IFC Backs Biovac’s Cholera Vaccine Trials

IFC Catalyzes Breakthrough in Africa’s Vaccine Manufacturing as Biovac Launches Cholera Vaccine Trials
Biovac, a client of the International Finance Corporation (IFC), has begun clinical trials for South Africa’s first domestically developed oral cholera vaccine. It is a major step for the continent’s health security and a signal of growing confidence in Africa-led vaccine manufacturing.
Once approved, the vaccine could be available by 2028. That would mean faster, more predictable access during cholera outbreaks and far less reliance on imported doses at moments when time matters most.
IFC’s role in building local capacity
IFC has played a central role in Biovac’s expansion over the past three years. The development financier led a consortium of local and international development finance institutions, including South Africa’s Industrial Development Corporation and the European Investment Bank, to mobilize funding for Biovac’s growth.
In 2023, IFC committed a US$7 million loan, in rand equivalent, to support the company’s scale up. Alongside the financing, IFC is also providing advisory support for the development of a new multi vaccine manufacturing facility in Cape Town.
The impact of this investment is significant. The new plant is expected to triple Biovac’s manufacturing capacity, introduce four to five additional vaccines, and support both traditional and mRNA platforms. For Africa, this represents a step change in the ability to respond to public health threats using locally produced solutions.
Why this matters for Africa
The cholera vaccine trials reflect a broader shift toward building resilient health systems across the continent. Local manufacturing reduces exposure to global supply disruptions, strengthens regulatory ecosystems, and improves the speed of response during outbreaks.
These efforts align with World Bank Group priorities focused on expanding domestic vaccine and pharmaceutical production, while strengthening regulation, delivery, and financing systems. The goal is not just access to vaccines, but real preparedness built into national and regional health systems.
As cholera continues to pose risks in several African countries, Biovac’s progress offers a practical example of how targeted investment and partnerships can translate into long term health security.






